A randomized, double-blind, placebo-controlled clinical study on the treatment of hypertension(grade 1,low to medium risk) with Qingda granules
- Conditions
- Essential hypertension
- Registration Number
- ITMCTR2024000123
- Lead Sponsor
- ong Linzi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Patients met the diagnostic criteria of hypertension level 1 according to the unified office blood pressure measurement, and the risk stratification was low and intermediate risk (according to the Chinese Guidelines for the prevention and treatment of Hypertension, revised edition 2018)
Not taking antihypertensive drugs within one month
TCM syndrome differentiation conforms to the liver-Yang hyperthyroidism syndrome
Age between 20 and 75 years old (including boundary values)
Sign the informed consent form
Patients with obvious liver and kidney diseases or glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase are 1.5 times higher than normal value, and creatinine and urea nitrogen are 2 times higher than normal value
Have the following diseases: Acute myocardial infarction, cerebrovascular accident, transient ischemic attack, large aneurysm or dissecting aneurysm, unstable angina pectoris, heart failure history of Grade II-IV (NYHA scale), atrioventricular block of grade II and above, sick sinus syndrome, bradycardia (heart rate < < 50 times/min) or patients with malignant or potentially malignant arrhythmias such as atrial fibrillation, serious mental diseases, diseases of the hematopoietic system, malignant tumors and other major diseases
Secondary hypertension, including but not limited to the following diseases: unilateral or double renal arteries, polycystic kidney disease, hyperaldosteronism, coarctation of the aorta, Cushing's syndrome, pheochromocytoma
Circadian rhythm reversal or irregular sleep pattern
pregnancy, lactation or family planning within 6 months
Have participated in or are participating in other clinical investigators within the last three months
Suspected or clear allergy to the study drug
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method